R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Locoregional Lymphadenectomy in the Surgical Management of Anorectal Melanoma
Daniel R. Perez,Atthaphorn Trakarnsanga,Jinru Shia,Garrett M. Nash,Larissa K. Temple,Philip B. Paty,Jose G. Guillem,Julio Garcia-Aguilar,Danielle M. Bello,Charlotte E. Ariyan,Richard D. Carvajal,Martin R. Weiser +11 more
TL;DR: Outcome following resection of anorectal melanoma is independent of locoregional lymph node metastasis; lymphadenectomy should be reserved for gross symptomatic disease.
Journal ArticleDOI
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Aljosja Rogiers,Ines Pires da Silva,Chiara Tentori,Carlo Tondini,Joseph M. Grimes,Megan H. Trager,Sharon Nahm,Leyre Zubiri,Michael Manos,Peter Bowling,Arielle Elkrief,Neha Papneja,Maria Grazia Vitale,April A.N. Rose,Jessica S.W. Borgers,Séverine Roy,Joanna Mangana,Thiago Pimentel Muniz,Tim Cooksley,Jeremy Lupu,Alon Vaisman,Samuel D. Saibil,Marcus O. Butler,Alexander M. Menzies,Matteo S. Carlino,Michael Erdmann,Carola Berking,Lisa Zimmer,Dirk Schadendorf,Laura Pala,Paola Queirolo,Christian Posch,Axel Hauschild,Reinhard Dummer,John B. A. G. Haanen,Christian U. Blank,Caroline Robert,Ryan J. Sullivan,Paolo A. Ascierto,Wilson H. Miller,F. Stephen Hodi,Karijn P M Suijkerbuijk,Kerry L. Reynolds,Osama E. Rahma,Paul Lorigan,Richard D. Carvajal,Serigne Lo,Mario Mandalà,Georgina V. Long +48 more
TL;DR: In this paper, the authors investigated whether ICI confers an additional risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with cancer.
Journal ArticleDOI
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
Funda Meric-Bernstam,Richard T. Lee,Bradley C. Carthon,Othon Iliopoulos,James W. Mier,Manish R. Patel,Nizar M. Tannir,Taofeek K. Owonikoko,Naomi B. Haas,Martin H. Voss,James J. Harding,Ramaprasad Srinivasan,Geoffrey I. Shapiro,Melinda L. Telli,Pamela N. Munster,Richard D. Carvajal,Yonchu Jenkins,Samuel H. Whiting,Johanna C. Bendell,Todd M. Bauer +19 more
TL;DR: Results from a Phase 1 study cohort evaluating the safety, efficacy, and recommended Phase 2 dose (RP2D) of CB-839 + Cabo in patients (pts) with mRCC as 2L+ therapy showed encouraging clinical activity and tolerability in heavily pretreatedmRCC pts, with response rates for cc mR CC comparing favorably to historical Cabo monotherapy.
Journal ArticleDOI
Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy
Journal ArticleDOI
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid
Kristen M. Beck,Joanna Dong,Larisa J. Geskin,Vincent Beltrani,Richard G. Phelps,Richard D. Carvajal,Gary K. Schwartz,Yvonne M. Saenger,Robyn D. Gartrell +8 more
TL;DR: The first case of a patient with metastatic cKIT mutated acral melanoma, brain metastasis, and pre-existing severe autoimmune bullous pemphigoid with stable and asymptomatic disease 10 months after treatment with pembrolizumab is described, suggesting that pembrology may confer more benefit than risk even in patients with known severe autoimmune conditions who require intermittent systemic immunosuppression.